News & press

Matt Franklin, MBA, appointed as Biofidelity Non-Executive Director

CAMBRIDGE, UK and RESEARCH TRIANGLE PARK, NORTH CAROLINA, USA, November 17,...

Read more

Biofidelity announces presentation of new data on novel genomic technology at AMP 2022

CAMBRIDGE, UK and RESEARCH TRIANGLE PARK, NORTH CAROLINA, USA, October 28, 2022...

Read more

New data demonstrates novel genomic technology provides ultra-sensitive detection of gene fusions from RNA

CAMBRIDGE, UK and RESEARCH TRIANGLE PARK, NORTH CAROLINA, USA, October 18, 2022...

Read more

Biofidelity granted key patents in US, Europe, and China

CAMBRIDGE, UK and RESEARCH TRIANGLE PARK, NORTH CAROLINA, USA, September 8,...

Read more

Biofidelity Raises $23M in Series A+ Financing led by Octopus Ventures to Launch ASPYRE Technology

Cambridge, UK, February 1, 2022 — Biofidelity, a pioneer in precision cancer...

Read more

Biofidelity Adds Lee N. Newcomer, MD to Scientific Advisory Board Ahead of ASPYRE Launch

Cambridge, UK, January 6, 2022 — Biofidelity, a pioneer in precision cancer...

Read more

New California Law Increases Access to Biomarker Testing for Late-Stage Cancer Patients

Cambridge, UK, October 13, 2021 — Biofidelity, a pioneer in precision cancer...

Read more

Successful alpha testing of Biofidelity’s ASPYRE-Lung reagents demonstrates breakthrough capabilities and ease of use

Cambridge, UK, 14 September 2021 – Biofidelity Ltd, the cancer diagnostics...

Read more

Biofidelity opens US headquarters and new cancer diagnostic laboratory

Cambridge, UK, 28 July 2021 – Biofidelity Ltd, the cancer diagnostics company,...

Read more

Biofidelity Announces Formation of Scientific Advisory Board

Cambridge, UK, 15 July 2021 – Biofidelity Ltd, the cancer diagnostics company,...

Read more

Biofidelity wins Start Up of the Year at the Cambridge Independent Science & Technology Awards

We are delighted and honoured to be recognised among this strong core of...

Read more

Biofidelity granted key patent in US for breakthrough cancer diagnostic technology

Cambridge, UK, 7 April 2021 – Biofidelity Ltd, the cancer diagnostics company,...

Read more

Biofidelity announces first peer reviewed publication of breakthrough ASPYRE technology

Cambridge, UK, 23 March 2021 – Biofidelity Ltd, the cancer diagnostics company,...

Read more

Biofidelity appoints Wendy J. Levin MD MS as Chief Medical Officer

US-trained oncologist & hematologist with over 15 years industry experience in...

Read more

Biofidelity appoints Robert Osborne as Chief Operating Officer

Biofidelity Ltd, the cancer diagnostics company, today announces the further...

Read more

Connect with us